Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:ADAPNASDAQ:AXLANASDAQ:BCLINASDAQ:ERYP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.91-1.6%$14.38$8.98▼$24.20$14.77M1.413,800 shs2,510 shsADAPAdaptimmune Therapeutics$1.58+3.9%$1.28$0.42▼$2.05$1.57B2.41.90 million shs1.18 million shsAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsBCLIBrainstorm Cell Therapeutics$0.60-9.1%$0.37$0.13▼$3.46$29.40M0.22967,226 shs1.28 million shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/A13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics-1.57%-5.59%-17.58%-17.98%+1.85%ADAPAdaptimmune Therapeutics+3.95%+18.80%-3.66%+128.95%+49.06%AXLAAxcella Health0.00%0.00%0.00%-8.89%-96.32%BCLIBrainstorm Cell Therapeutics-9.06%+18.38%+67.23%+127.18%-67.38%ERYPERYTECH Pharma0.00%0.00%+3.71%-36.86%+235.82%[BUY ALERT] Our #1 A.I. Stock for March (Ad)It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AADAPAdaptimmune Therapeutics1.8503 of 5 stars3.03.00.00.02.51.70.6AXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics4.3439 of 5 stars3.05.00.04.73.80.00.6ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AADAPAdaptimmune Therapeutics2.00Hold$5.00216.46% UpsideAXLAAxcella HealthN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics2.00Hold$10.001,566.11% UpsideERYPERYTECH PharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$118.57M0.12N/AN/A$77.13 per share0.15ADAPAdaptimmune Therapeutics$60.28M26.06N/AN/A$0.04 per share39.50AXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/AERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$65.92M-$17.11N/A∞N/A-14.35%-21.45%-4.25%4/1/2024 (Confirmed)ADAPAdaptimmune Therapeutics-$113.87M-$0.55N/AN/AN/A-188.90%-155.39%-43.42%5/10/2024 (Estimated)AXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%3/28/2024 (Estimated)BCLIBrainstorm Cell Therapeutics-$24.28M-$0.44N/AN/AN/AN/AN/A-310.78%4/4/2024 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest ADAP, AXLA, BCLI, ERYP, and ACOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.071.591.21ADAPAdaptimmune TherapeuticsN/A2.852.85AXLAAxcella HealthN/A0.800.80BCLIBrainstorm Cell TherapeuticsN/A0.240.24ERYPERYTECH Pharma0.323.653.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ADAPAdaptimmune Therapeutics31.37%AXLAAxcella Health65.07%BCLIBrainstorm Cell Therapeutics14.33%ERYPERYTECH Pharma1.09%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ADAPAdaptimmune Therapeutics17.37%AXLAAxcella Health2.20%BCLIBrainstorm Cell Therapeutics5.45%ERYPERYTECH Pharma1.94%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataADAPAdaptimmune Therapeutics449994.21 million821.52 millionOptionableAXLAAxcella Health112.95 million2.88 millionOptionableBCLIBrainstorm Cell Therapeutics4248.98 million46.31 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableADAP, AXLA, BCLI, ERYP, and ACOR HeadlinesSourceHeadlinePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Marketfinanznachrichten.de - February 21 at 2:25 PMRoyalty Pharma PLC Class A RPRXmorningstar.com - January 19 at 5:32 PMErytech Pharma S.A.: Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMfinanznachrichten.de - June 28 at 6:41 PMPhaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMfinance.yahoo.com - June 28 at 6:41 PMMonthly information related to total number of voting rights and shares composing the share capital - June 26, 2023finance.yahoo.com - June 27 at 1:38 PMERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeuticsfinance.yahoo.com - June 26 at 5:27 PMERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023finance.yahoo.com - June 23 at 7:40 PMErytech Pharma S.A.: ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitfinanznachrichten.de - June 20 at 9:10 PMERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitmarkets.buffalonews.com - June 20 at 4:10 PMTech, Pharma Stocks Lead European Equities Higher in Thursday Tradingmsn.com - June 15 at 1:13 PMUpdate on Erytech merger with Pherecydes Pharmathepharmaletter.com - June 15 at 8:13 AMERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharmafinance.yahoo.com - June 14 at 2:41 PMErytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closerbenzinga.com - June 13 at 4:31 PMMonthly information related to total number of voting rights and shares composing the share capital _May 31, 2023finance.yahoo.com - June 13 at 4:31 PMErytech Pharma S.A.: ERYTECH Responds to Akkadian's Disinformationfinanznachrichten.de - June 12 at 6:13 PMERYTECH Responds to Akkadian’s Disinformationfinance.yahoo.com - June 12 at 6:13 PMErytech Pharma S.A.: ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydesfinanznachrichten.de - June 5 at 3:52 AMERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydesfinance.yahoo.com - June 5 at 3:52 AMERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023finance.yahoo.com - May 24 at 5:42 PMPharma Stocks Lead European Equities Sharply Lower in Wednesday Tradingmsn.com - May 24 at 12:42 PMPHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech Pharmabusinesswire.com - May 23 at 9:41 PMERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydesfinance.yahoo.com - May 23 at 4:40 PMPharma Stocks Lead European Equities Modestly Lower in Tuesday Tradingmsn.com - May 23 at 11:40 AMEuropean Equities Rise in Friday Trading, Poised to End Week Highermsn.com - May 19 at 12:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?3 Small-Cap Leaders Poised for Significant GrowthMarch 13, 2024 7:05 AMView 3 Small-Cap Leaders Poised for Significant GrowthAll Headlines Company DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Adaptimmune TherapeuticsNASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Axcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Brainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.